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Consumption of antibiotics 
within ambulatory care in Malta
Abstract
Background: Antibiotic use is recognised as the most 
important driver for the development of antimicrobial resistance 
in community pathogens. Surveillance is therefore critical for 
improvement programmes. 
Methods: Antimicrobial distribution data for the years 
2007 to 2009 were collected retrospectively by the National 
Antibiotic Committee from all licensed wholesale distributors 
(WSL) in Malta and analysed according the World Health 
Organization Anatomical Therapeutic Chemical classification 
(ATC) level 4 criteria.
Results: Overall consumption increased from 18.6 defined-
daily-doses/1000-inhabitant-days (DID) in 2007 to 22.7 DID 
in 2008 and reached 24.4 DID in 2009 - an increase of more 
than 30% over the three years, Penicillins with beta-lactamase 
inhibitor increased in volume (7.1 to 8.8 DID) but decreased in 
proportion (38.4% to 36.0%) between 2007 and 2009. On the 
other hand, second generation cephalosporins increased in both 
volume and proportion (2.8 to 5.4 DID; 15.0% to 22.0%). The 
proportion for macrolides remained stable at approximately 
16% but the volume of use again increased (2.9 DID to 3.9 DID). 
Fluoroquinolone proportion decreased from 9.1% to 6.8%, 
maintaining a stable volume of use in the region of 1.7 DID.
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Conclusions: Antibiotic consumption in Malta has shown 
a consistent increasing trend over the past three years, despite a 
reduction in over-the-counter acquisition. Furthermore, there 
is evidence of a strong, and possibly unjustified, prescription of 
wide spectrum antibacterials. This is potentially an important 
driver for documented resistance in Streptococcus pneumoniae 
and Escherichia coli and needs to be addressed at a national 
level.
Introduction
Antimicrobial consumption is recognised as an important 
driver for resistance amongst community pathogens, especially 
Streptococcus pneumoniae and Escherichia coli.1 For this 
reason, surveillance of antibiotic use has been undertaken 
within most of the countries of the European Union.2 The data 
sources for these surveillance systems have normally been either 
reimbursement or sales statistics. Malta has been participating 
in the European Surveillance of Antimicrobial Consumption 
(ESAC) since its inception in 2001 but has only managed to 
contribute hospital statistics. Indeed, in a 2006 publication, 
Vander Stichele and colleagues commented on the lack of 
availability of ambulatory care in Malta stating that “for 14 of the 
15 sets of valid hospital data (all except Malta) the ambulatory 
care data were also available within the ESAC data collection 
systems, and hence total antibiotic exposure could be calculated, 
as well as the mix between ambulatory and hospital care.”3 
Due to the absence of a reimbursement system in ambulatory 
medical care in Malta, the majority of antibiotic prescriptions are 
purchased out-of-pocket from private community pharmacies. 
In addition, pharmacies do not keep an electronic database of 
prescriptions dispensed and, therefore, data at prescription 
level is not available either. For this reason, it is not possible to 
utilise the usual methods adopted in EU countries to perform 
ambulatory care antibiotic consumption. As a result, the only 
feasible way of collecting antimicrobial use data is through 
wholesalers’ distribution records to pharmacy outlets. This 
became possible following national legislation establishing the 
National Antibiotic Committee in 2008 (legal notice 122/2008) 
as an intersectoral mechanism (ISM) with a legal mandate to 
undertake antibiotic use surveillance  (https://ehealth.gov.mt/
healthportal/others/regulatory_councils/national_antibiotic_
committee/introduction.aspx). The presence of such a national 
ISM, as well as continuous consumption surveillance, is 
mandated by European Council Recommendation of 15.11.2001 * corresponding author
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on the Prudent Use of Antimicrobial Agents in human medicine 
(2002/77/EC)(http://europa.eu/legislation_summaries/
public_ health/threats_to_health/c11569_en.htm). 
It is well established that up to 50% of antimicrobial agents 
prescribed in the community setting are often inappropriate.4 
This is often the result of addressing the wrong pathogen (e.g. 
use for viral upper respiratory tract infections) or the wrong 
drug (inappropriate choice of antimicrobial and/or inadequate 
dose). Wide spectrum antibiotics are well known to predispose 
towards resistance much more strongly than narrow spectrum 
equivalents.5 Indeed unjustified perceptions of resistance, 
based on inadequate knowledge of the local epidemiology, may 
result in unnecessary prescription of wide spectrum agents.6 
Antimicrobials prescribed in the community setting, especially 
for respiratory infections, account for the biggest proportion 
of antibiotics in any country.6 It is therefore critical to identify 
and address inappropriate prescribing patterns. This can be 
undertaken by quantifying antimicrobial use in the ambulatory 
care sector in order to identify any apparent or significant 
changes in consumption trends, both overall as well as for 
different drug classes. 
Methods
Licensed wholesale distributors (WSL) were requested 
to submit their antimicrobial distribution records for the 
year 2007, 2008 and 2009. Data were submitted in a format 
compatible with Microsoft Excel 2003® using the World Health 
Organization (WHO) anatomical therapeutic chemical (ATC) 
classification and defined daily dose (DDD).7 Information was 
only requested about systemic agents in line with the ESAC 
methodology.8 Information collected included: international 
non-proprietary name (iNN), dosage form, number of doses 
per package (for oral suspensions this is equivalent to total 
volume divided by 5ml unit dose), unit dose (in grams per 
tablet/capsule/phial/5ml dose), and route of administration 
(oral/rectal/parenteral). Data were sent via email to nac.
mhec@gov.mt. Following submission, data were cleaned and 
validated to remove any errors in data entry. When such 
inaccuracies were minimal these were edited centrally. If 
the extent of incorrect data entered was more complex, the 
WSL was informed about the necessary steps to be taken 
for correcting the issues identified. The Government Health 
Services database was utilized in order to extract data for public 
community pharmacies. Such entitlement was related either 
to schedule II (Pink Card holders) and/or specified chronic 
medical conditions (Schedule V conditions with entitlement 
to antibiotics). Data for the public sector included distribution 
data of the Government Pharmaceutical Services (GHPS) to both 
Health-centre dispensaries, out-patients dispensary of St. Luke’s 
Hospital (only for 2007) and subsequently Mater Dei Hospital 
out-patient dispensing from 2008 including the Pharmacy of 
your choice (POYC) scheme.
Special attention was paid to avoid duplicate entries from 
WSLs who distribute to private community pharmacies as well 
as the GHPS and/or other WSL’s. Therefore, distribution by one 
WSL to another WSL or GHPS were excluded from the analyses; 
only distribution data to ‘private community pharmacies’ were 
included from the data provided by WSL, in addition to the 
GHPS distribution data. 
Annual returns were analysed separately using a metadata 
set on Microsoft Excel 2003®. Data were aggregated at ATC 
level 5 (ATC5), i.e., generic name, but reported only at the 
fourth ATC level (ATC4 e.g., penicillin with beta-lactamase 
inhibitor – J01CR) to maintain confidentiality about specific 
products and brands. For the sake of comparison between 
public and private sector, data were aggregated at ATC level 3 
(ATC3 e.g., penicillins – J01C). Data were expressed as DDD per 
1000-inhabitant days (DID) to take into account demographic 
changes from year to year.
Results 
All the licensed wholesale Maltese distributors replied to the 
respective notification letters by submitting either distribution 
data for the respective years (2007-2009) or a nil return stating 
that no antimicrobial agents were included in their distribution 
portfolio for the local market. Table 1 shows the consumption 
in DID and the proportion (%) per year for the six most utilised 
antimicrobial classes (ATC4) and the total annual DID. It also 
shows the percentage change in DID from 2007 to 2009. Overall 
consumption of antimicrobial agents for systemic use increased 
from 18.6 DID in 2007 to 24.4 DID in 2009. This corresponds 
to a 30% increase in consumption over the three years. 
Penicillins with beta-lactamase inhibitor (J01CR) increased in 
volume (7.1 to 8.8 DID) but decreased in proportion (38.4% to 
36.0%) between 2007 and 2009. On the other hand, second 
generation cephalosporins (J01DC) increased in both volume 
and proportion over the three years (2.8 to 5.4 DID; 15.0% to 
22.0%). The proportion for macrolides (J01FA) remained stable 
at approximately 16% but the actual use volume increased from 
2.9 DID to 3.9 DID. Fluoroquinolone use decreased from 9.1% 
to 6.8% maintaining a stable volume of use around 1.7 DID.
Analysis of the data by distribution type (public versus 
private community pharmacies) showed a great disparity in 
drug classes utilised (Table 2). More than 90% of antibiotics 
distributed [mean: 91.8%; 95% CI: 88.4-95.2%] were procured 
by private pharmacies (Figure 1), indicating that the vast 
majority of national consumption in Malta is very much 
dependent on private sector dispensing.
The proportion of antibiotic classes at ATC level 4 differed 
considerably between the private and public sector as shown 
in Table 2. Despite these differences the most used drug-class 
in both sectors was penicillin with beta-lactamase inhibitor 
(J01CR), specifically co-amoxiclav. Narrower spectrum 
penicillins (J01CE) and nitrofuran derivatives (J01XE) were 
used rarely in the private sector and appeared in the top 12 
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  Year         2007  2008  2009 % Δ in    Δ in 
      DID*    proportion 
ATC4                  DID*     %  DID*    % DID*    %       (2007-9)   (2007-9)
J01CR (penicillin + beta-   7.1 38.4 8.3 36.5 8.8 36.0 23.0% -2.3%
lactamase inhibitor) 
J01DC (2nd generation    2.8 15.0 4.7 20.7 5.4 22.0 93.2% 7.1%
cephalosporins) 
J01FA (macrolides)    2.9 15.7 3.5 15.5 3.9 15.8 32.0% 0.1%
J01MA (fluoroquinolones)  1.7 9.1 1.8 7.8 1.7 6.8 -1.3% -2.2%
J01CA (extended spectrum   1.4 7.4 1.4 6.0 1.3 5.3 -6.4% -2.1%
penicillins) 
J01AA (tetracyclines)   0.9 5.0 1.1 4.8 1.1 4.6 20.7% -0.4%
Others (30 classes)    1.8 9.5 2.0 8.7 2.3 9.4 29.5% -0.1%
Total consumption    18.6 100 22.7 100 24.4 100 31.0% -
Table 1. Total consumption in ambulatory care for the years 2007-2009 and changes between 2007 and 2009
most used antibiotics only for the public sector. On the contrary 
extended-spectrum drugs like 2nd generation cephalosporins 
(J01DC) and fluoroquinolones (J01MA) ranked high in the 
private pharmacies.
Data from the Microbiology Laboratory of Mater Dei 
Hospital indicated that the increase in consumption of 2nd 
generation cephalosporins during the study period was 
accompanied by an increase in resistance to the same class of 
drugs in Escherichia coli isolates of likely community origin 
(Health-centres and Accident & Emergency Department) as 
shown in Figure 2. 
The drug class that showed the highest increase in 
consumption between 2007 and 2009 were the neuraminidase 
inhibitors. This increase coincides with the H1N1 pandemic 
influenza during 2009, and was observed in both the private 
as well as the public sector.
Key: *DID = defined daily doses per 1000 inhabitant days: Δ = change
Discussion
Our surveillance data confirm that consumption of 
antibiotics in ambulatory care within Malta shows clear evidence 
of a consistent increase over the past years, which seems to be 
predominantly attributable to an increase in the use of second 
generation cephalosporins. Nevertheless, penicillins with beta-
lactamase inhibitor, despite decreasing in the proportion, still 
showed a net increase in DID. This data are very worrying. 
Penicillins with beta lactamase inhibitors, cephalosporins and 
fluoroquinolones are well recognised drivers for Clostridium 
difficile enterocolitis even in community settings.9 Above all, it 
is a matter of grave concern that ambulatory care consumption 
in Malta relies almost exclusively on four antimicrobial classes 
- all of which are highly broad spectrum. Penicillins with 
beta-lactamase-inhibitor, second generation cephalosporins, 
macrolides and fluoroquinolones have all been strongly 
linked with the development of resistance. Cephalosporin and 
fluoroquinolone use is a major driver for methicillin resistance 
in Staphylococcus aureus (MRSA).5 Macrolide resistance and 
penicillin non-susceptibility in Streptococcus pneumoniae poses 
major challenges in the treatment of community associated 
pneumonia and meningitis; in both cases, emergence has been 
correlated with consumption patterns.9-11 Macrolide resistance is 
also a concern in Streptococcus pyogenes, where again macrolide 
consumption has been implicated.12 The latest emerging threat 
is the development of resistance within Escherichia coli to 
cephalosporins and fluoroquinolones5,9 Indeed, the reported 
local increase in use of 2nd generation cephalosporins was 
accompanied by a corresponding increase in resistance 
within community E. coli isolates. This association between 
consumption of cephalosporins and extended-spectrum-beta-
Figure 1: Distribution of consumption by private and 
public sectors respectively. The DID and percentage of 
total DID is shown for the private sector
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Private Community Pharmacies
Antimicrobial class (ATC4 level)     2007  2008  2009
J01CR (penicillin + beta-lactamase inhibitor)    36.0%  35.4%  33.2%
J01DC (2nd generation cephalosporins)    16.7%  21.8%  24.3%
J01FA (macrolides)      17.0%  16.2%  17.2%
J01MA (fluoroquinolones)       9.9%   8.2%   7.5%
J01CA (extended spectrum penicillins)     7.2%    5.7%   4.3%
J01AA(tetracyclines)       5.4%   5.0%   4.9%
P01AB (oral/rectal metronidazole)      1.0%   2.0%   1.7%
D01BA (systemic antimycotics for dermatological use)    1.7%    1.5%   1.4%
J01FF (lincosamides)       1.4%   0.9%   0.8%
J01EE (sulphanamides/trimethoprim)    0.8%   0.7%   0.6%
J01DD (3rd generation cepholosporins)    0.5%   0.7%   0.9%
J05AH (neuraminidase inhibitor)     0.4%   0.1%   1.2%
Others        2.1%   1.8%   2.0%
Table 2. Proportion of antibacterials within private and public settings (Showing the top 12 drug classes)
Public Community Pharmacies
Antimicrobial class (ATC4 level)     2007  2008  2009
J01CR (penicillin + beta-lactamase inhibitor)    58.0%  59.3%  64.1%
J01CA (extended spectrum penicillins)     9.4%  11.4%  15.6%
P01AB (oral/rectal metronidazole)      5.2%   4.3%    2.9%
J01FA (macrolides)       4.4%   2.1%   1.7%
J01CE (narrow spectrum penicillins)      4.0%    3.3%   1.2%
J01DB (1st generation cephalosporins)      3.1%   3.3%   1.7%
J01EE (sulphanamides/trimethoprim)     3.2%   3.1%   1.4%
D01BA (systemic antimycotics for dermatological use)    1.5%   1.1%   1.6%
J01XE (nitrofuran derivatives)      1.7%   1.5%   1.4%
J05AH (neuraminidase inhibator)     0.0%   0.0%   3.2%
J01FF (lincosamides)       1.5%   1.3%   0.9%
J01AA(tetracyclines)      1.6%  0.7%   1.0%
Others        6.7%   8.4%  1.99%
lactamases (ESBL) has already been documented in other 
countries.13 This resistance originating from the community 
has a potential knock-on effect on hospitals as it predisposes 
to subsequent nosocomial cross-transmission of resistant Gram 
negative bacteria. This in turn has significant patient safety 
repercussion due to potential ineffective empiric antibiotics and 
requirement for parenteral third line antimicrobials following 
therapeutic failure in the community.14 Indeed, ESBL producing 
bacteria which initially originated in the community are now 
recognised as important pathogens responsible for healthcare 
associated infections.15 
It should additionally be remarked that systemic agents are 
not the only pharmaceuticals that induce antibiotic resistance. 
Topical antibiotics are equally problematic in this respect. The 
National Antibiotic Committee’s newsletter issued for the 2010 
European Antibiotic Awareness Day (EAAD) (https://ehealth.
gov.mt/ download.aspx?id=4904) highlighted the increase in 
fusidic acid resistance in community Staphylococcus aureus 
strains which is almost certainly attributable to over and misuse 
of fusidic acid topical preparations in Malta. Indeed a novel 
strain of MRSA has been identified in Malta that differs from 
previously identified strains only by the presence of a fusidic acid 
resistant gene.16 This type of MRSA is increasingly being isolated 
even in patients without a previous history of hospitalisation.  
Maltese antimicrobial consumption for 2007 was close to the 
median reported by the European Surveillance of Antimicrobial 
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Figure 2. Trends in consumption of 2nd generation 
cephalosporins and percentage resistance (%R) in 
Escherichia coli isolates obtained from Health Centres 
(HC) and Accident & Emergency Dept – St. Luke’s/Mater 
Dei Hospital (A&E) for the years 2007 to 2009
Consumption (ESAC) network for 24 European countries during 
the same time period.17 This was rather surprising because 
previous publications had suggested a high level of antibiotic 
consumption in the country.18 The 2009 ‘Special Eurobarometer 
338’ survey (http://ec.europa.eu/public_ opinion/archives/
ebs/ebs_338_en.pdf) showed that 55% Maltese respondents 
said that they had taken an antibiotic in the previous year; this 
was the second highest figure in the whole EU.19 This discrepancy 
could be explained in a number of ways. WSLs could have 
underreported distribution sales; we do not believe this to be 
the case since the patterns of the notified over the three years 
are consistent and credible. A more likely explanation could be 
that inadequately lower doses are utilised in Malta. A typical 
example would be co-amoxiclav 375mg being prescribed where 
the 625mg would be more appropriate, as is the norm in EU 
countries. The 2009 Eurobarometer study also confirmed that 
the vast majority of antibiotic consumption in Malta is the 
result of medical prescription. Indeed a consistent and credible 
reduction in over the counter dispensing has been seen in the 
past decade. The self-medication rate of 19% that was reported 
in 2001,20 had already fallen to 5.6% by 2003;21 the 2009 
Eurobarometer study confirmed a further reduction to 4%, 
which falls practically within the EU median. This improvement 
can be attributed to annual campaigns and initiative for 
better antibiotic use addressed at the public as well as doctors 
and pharmacists, especially related to the annual EAAD.22 
Comparison with  European ambulatory care data also highlights 
the negligible consumption in Malta of narrow spectrum drugs 
such as first generation cephalosporins, narrow-spectrum 
penicillins and anti-staphylococcal penicillins (Figure 3).23 It is 
not a coincidence that Scandinavian countries have managed to 
avoid significant resistance problems over the past three decades 
when up to half of their ambulatory care antibiotics prescribed 
are still phenoxymethyl- and benzyl- penicillins.24
Figure 3. Proportion of narrow spectrum 
antibacterials in ambulatory care across 28 European 
countries and Israel (arrow indicates Malta data)23
Our healthcare-system is different from that found in 
most European countries where individual prescription 
and indication data are available as they are linked to 
reimbursement. Therefore, Eurobarometer provides the only 
possible information linking antimicrobial use for inappropriate 
indications (colds and influenza); Malta had one of the 
higher proportion of respondents (26%) who were prescribed 
antibiotics for “influenza”.19
This first effort to collect national antibiotic consumption 
statistics in Malta has collected, for the first time, validated 
national statistics for use of these pharmaceuticals. One possible 
limitation of these data lies in the fact that some WSL ceased 
operation since the start of the ongoing surveillance and were 
therefore included only in the initial years whilst some others 
started operations and were included in later years. However, 
we do not believe this influenced significantly the overall 
consumption as antimicrobial agents are dispensed from licensed 
pharmacies, the number of which did not change considerably. 
Neither did trends in the Maltese population with an average 
estimated population for the 3 years of 412,290 inhabitants 
(source: http://www.nso.gov.mt/demographic reviews: 2007 
[410,290]; 2008 [413,609] and; 2009 [412,970]). Therefore, 
any change in volume of antibiotic use per 1000-inhabitant days 
cannot be attributed to changes in population over the years. 
Furthermore, the increase can neither be due to seasonality 
since time scales are equal.
An unavoidable limitation of the data collection was our 
inability to breakdown the data into monthly or quarterly 
periods to assess seasonal variations in prescribing. Indeed 
seasonal variation has been strongly reported from the high 
consuming countries of Southern Europe.25 This could be equally 
relevant in the local setting and suggests the need for more 
detailed surveillance to assess the degree of seasonal variability 
in antibiotic prescribing in Malta.  
In conclusion, our results confirm a heavy reliance on 
antibiotics, especially those of broad spectrum formulation, by 
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local prescribers. Indeed, the most striking characteristic of the 
local data was the negligible consumption of narrow spectrum 
and penicillinase resistant penicillins as well as first generation 
cephalosporins. This heavy dependence on wide spectrum 
antibiotics at the expense of narrow spectrum products is not 
justified by evidence based international guidelines nor by local 
resistance epidemiology. It is arguably the most likely driver 
for the documented local increase in resistance in macrolide 
resistant Streptococcus pneumoniae, ESBL producing 
Escherichia coli and MRSA.26 It also highlights the challenge 
facing the National Antibiotic Committee to foster better 
antibiotic prescribing habits in local medical practitioners. This 
is not an easy task, especially as national culture is a key driver 
behind inappropriate prescribing.27  It is nevertheless a challenge 
that needs to be addressed since continuation of current trends 
risks a vicious cycle of ever increasing and expanding resistance 
that will have a direct patient safety repercussion on the Maltese 
population.
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